Latest Imatinib Stories
PHILADELPHIA, Aug. 25 /PRNewswire/ -- In celebration of a seminal discovery in cancer biology, Fox Chase Cancer Center will host the Philadelphia Chromosome Symposium: Past, Present and Future, on September 28, 2010, from 8 a.m. to 7 p.m.
COLUMBUS, Ohio, Aug. 24 /PRNewswire/ -- Today, leukemia patients who have struggled with cancer therapy resistance and intolerance will now have more options thanks to targeted drug therapy.
Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML).
WHITE PLAINS, N.Y., July 12 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new grants through its prestigious Marshall A.
EAST HANOVER, N.J., June 17 /PRNewswire/ -- Following a priority review, the US Food and Drug Administration (FDA) has approved TasignaÂ® (nilotinib) 150 mg capsules for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Approval expands use in treatment of rare type of leukemia SILVER SPRING, Md., June 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed.
MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy.
Two drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication.
EAST HANOVER, N.J., June 4 /PRNewswire/ -- Novartis announced today 18-month results (median follow-up) showing that TasignaÂ® (nilotinib) capsules significantly surpass the efficacy of GleevecÂ® (imatinib mesylate) tablets* in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase(1).
EAST HANOVER, N.J., June 2 /PRNewswire/ -- Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG, today announced that nearly 170 abstracts highlighting investigational uses of current therapies and investigational agents in the Novartis Oncology portfolio will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) from June 4 through June 8 in Chicago, IL (1).
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).